Verastem (VSTM) 2025 Update / Briefing June 02, 2025 12:00 PM ET Speaker0 Thanks everybody for coming. Very excited You're familiar with our story. We're really focused on RAFmAbK driven cancers. Within our own portfolio, we've got the RAFmec inhibitor of vutametinib, defactinib, which is our FAC inhibitor and then the G12D inhibitor. In addition to that, we do have two other targets as part of our Genfleet collaboration that we haven't disclosed. And so both within our own portfolio and then combining with ...